| Literature DB >> 26731101 |
Hongxu Du1, Shuaibing Zhang1, Meiyun Song1, Yixuan Wang1, Ling Zeng1, Yun Chen1, Wen Xiong1, Jingjing Yang1, Fangke Yao1, Yi Wu1, Deyun Wang1, Yuanliang Hu1, Jiaguo Liu1.
Abstract
Because polysaccharide and flavone ingredients display good antiviral activity, we developed a flavone/polysaccharide-containing prescription that would be effective against duck viral hepatitis (DVH) and investigated its hepatoprotective effects. Flavones were derived from Hypericum japonicum (HJF) (entire herb of Hypericum japonicum Thunb) and Salvia plebeia (SPF) (entire herb of Salvia plebeia R. Br.), and polysaccharides were derived from Radix Rehmanniae Recens (RRRP) (dried root of Rehmannia glutinosa Libosch). This prescription combination was based on the theory of syndrome differentiation and treatment in traditional Chinese veterinary medicine. In vitro and in vivo experiments were conducted using the three single ingredients compared to the combined HRS prescription to determine their anti-duck hepatitis A viral (anti-DHAV) activity. The results showed that all experimental conditions displayed anti-DHAV activity, but the HRS prescription presented the best effect. To further investigate the hepatoprotective effect of the HRS prescription on DHAV-induced hepatic injury, we tested the mortality rate, the hepatic pathological severity score, plasma biochemical indexes of hepatic function, blood DHAV gene expression levels and peroxidation damage evaluation indexes and then analyzed correlations among these indexes. The results demonstrated that the HRS prescription significantly decreased the mortality rate, reduced the severity of hepatic injury, decreased the hepatic pathological severity score, depressed blood DHAV gene expression levels, and returned the indexes of hepatic function and peroxidation almost to a normal level. These results indicate that the HRS prescription confers an outstanding hepatoprotective effect, and we expect that it will be developed into a new candidate anti-DHAV drug.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26731101 PMCID: PMC4701506 DOI: 10.1371/journal.pone.0146046
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The A570 values and viral inhibitory rates on DEHs.
| Treatment | Concentration (μg/mL) | A570 | Viral inhibitory rate (%) | Treatment | Concentration (μg/mL) | A570 | Viral inhibitory rate (%) |
| HJF | 12.500 | 0.537±0.005c | 30.3 | SPF | 2000 | 0.273±0.002cd | 6.6 |
| 6.250 | 0.564±0.003b | 34.6 | 1000 | 0.306±0.007b | 20.2 | ||
| 3.125 | 0.579±0.008b | 37.0 | 500 | 0.289±0.007bc | 13.2 | ||
| 1.563 | 0.541±0.009c | 30.9 | 250 | 0.279±0.005cd | 9.1 | ||
| 0.781 | 0.444±0.006d | 15.4 | 125 | 0.279±0.007cd | 9.1 | ||
| CC | 0.624±0.007a | 0.500±0.011a | |||||
| VC | 0.348±0.006e | 0.257±0.009c | |||||
| Treatment | Concentration (μg/mL) | A570 | Viral inhibitory rate (%) | Treatment | Concentration (μg/mL) | A570 | Viral inhibitory rate (%) |
| RRRP | 1250 | 0.449±0.009d | 11.2 | HRS | 2500 | 0.352±0.003b | 88.9 |
| 625 | 0.448±0.015cd | 10.9 | 1250 | 0.387±0.005a | 103.9 | ||
| 312.500 | 0.473±0.024bc | 18.9 | 625 | 0.282±0.010c | 59.0 | ||
| 156.250 | 0.516±0.019b | 32.6 | 312.500 | 0.200±0.008d | 23.9 | ||
| 78.125 | 0.478±0.023bc | 20.5 | 156.250 | 0.219±0.004d | 32.1 | ||
| CC | 0.727±0.010a | CC | 0.378±0.009a | ||||
| VC | 0.414±0.008d | VC | 0.144±0.003e |
a–e Data within a column without the same superscripts differ significantly (p < 0.05).
Results of the three single ingredients and HRS prescription anti-DVH effects.
| Group | Samples (feathers) | Final deaths (feathers) | Time of death ending (hpi) | Mortality rate (%) |
|---|---|---|---|---|
| HJF group | 35 | 20 | 54 | 57.1ab |
| SPF group | 35 | 22 | 120 | 62.9ab |
| RRRP group | 35 | 21 | 120 | 60.0ab |
| HRS group | 35 | 15 | 108 | 42.9b |
| VC group | 35 | 26 | 144 | 74.3a |
| BC group | 35 | 0 | - | 0c |
a−c Data within a row without the same superscripts differ significantly (p < 0.05).
*Time of death ending was unable to record for no deaths appeared.
hpi: hours post-injection.
Fig 1The curative effect of the HRS prescription and the Visual changes in pathological anatomy in each group.
(I) The curative effect of the HRS prescription. a-c Bars in the same index without the same superscripts differ significantly (p < 0.05). (II) Visual changes in pathological anatomy in the HRS (A), VC (B) and BC (C) groups. Arrows a and c: hemorrhagic spots; arrow b: ecchymosis.
The number of ducklings corresponding to the different scores in each group.
| Group | 0 point (feathers) | 1 points (feathers) | 2 points (feathers) | 3 points (feathers) | 4 points (feathers) | 5 points (feathers) | Average score (points) |
|---|---|---|---|---|---|---|---|
| HRS group | 17 | 6 | 9 | 6 | 4 | 3 | 1.6b |
| VC group | 7 | 3 | 5 | 8 | 12 | 10 | 3.0a |
| BC group | 45 | 0 | 0 | 0 | 0 | 0 | 0c |
a-c Data within a row without the same superscripts differ significantly (p < 0.05).
Results of hepatic function biochemical indexes in each group.
| Index | Time (hpi) | HRS group | VC group | BC group |
|---|---|---|---|---|
| ALT (IU/L) | 4 | 25.2±3.9a | 27.0±3.3a | 27.2±2.4a |
| 8 | 33.2±3.0b | 43.0±2.8a | 28.6±1.6b | |
| 54 | 41.3±3.2b | 67.4±3.7a | 36.8±1.0b | |
| AST (IU/L) | 4 | 13.0±0.8a | 14.0±2.1a | 12.3±1.7a |
| 8 | 20.5±0.6ab | 28.8±5.2a | 14.0±1.0b | |
| 54 | 16.7±4.7ab | 21.2±2.1a | 12.6±0.8b | |
| TP (g/L) | 4 | 24.7±1.1a | 25.4±1.1a | 24.7±0.7a |
| 8 | 27.8±1.0a | 26.2±0.40a | 28.0±1.2a | |
| 54 | 25.8±1.1a | 25.9±0.6a | 28.1±0.5a | |
| ALB (g/L) | 4 | 10.3±0.5a | 10.7±0.6a | 10.9±0.5a |
| 8 | 11.3±0.3a | 11.1±0.3a | 12.3±0.6a | |
| 54 | 11.4±0.4ab | 10.8±0.1b | 12.2±0.5a | |
| LDH (IU/L) | 4 | 379.8±18.6a | 403.3±47.9a | 375.8±54.5a |
| 8 | 474.0±10.6b | 595.0±14.4a | 307.8±31.0c | |
| 54 | 1233.3±147.3b | 4743.0±570.8a | 312.2±13.7c |
a-c Data within a row without the same superscripts differ significantly (p < 0.05).
hpi: hours post-injection.
Fig 2Peroxidation damage evaluation indexes at 8 hpi and 54 hpi (hpi: hours post-injection).
a-c Bars in the same index at the same time point without the same superscripts differ significantly (p < 0.05).
Fig 3Relative DHAV gene expression levels in each group.
Viral gene expression level in the VC group at 4 hpi was set to 1. a-c Bars at the same time point without the same superscripts differ significantly (p < 0.05). hpi: hours post-injection.
The Pearson correlation coefficients among hepatic function indexes, peroxidation damage evaluation indexes, mortality rate, viral gene expression level and hepatic pathological severity score at 54hpi.
| ALT | AST | LDH | ALB | hepatic pathological severity score | |
|---|---|---|---|---|---|
| SOD | -0.983 | -0.855 | -0.970 | -0.794 | 0.010 |
| CAT | -0.981 | -0.849 | -0.967 | -0.787 | 0.021 |
| GSH-Px | -0.976 | -0.990 | -0.988 | -0.969 | -0.385 |
| NOS | 0.681 | 0.896 | 0.725 | -0.939 | 0.839 |
| MDA | 0.924 | 0.730 | 0.899 | -0.651 | -0.216 |
| T-AOC | -0.849 | -0.608 | -0.815 | 0.518 | 0.373 |
| Viral gene expression level | 0.979 | 0.988 | 0.990 | -0.965 | 0.976 |
| Mortality rate | 0.394 | 0.693 | 0.450 | -0.767 | 0.974 |
* p < 0.05.
** p < 0.01.
hpi: hours post-injection.